» Articles » PMID: 38449903

A Comprehensive Review on Pharmacologic Agents, Immunotherapies and Supportive Therapeutics for COVID-19

Overview
Journal Narra J
Date 2024 Mar 7
PMID 38449903
Authors
Affiliations
Soon will be listed here.
Abstract

he emergence of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout the world. As urgency is a necessity, most efforts have focused on identifying small molecule drugs that can be repurposed for use as anti-SARS-CoV-2 agents. Although several drug candidates have been identified using method and studies, most of these drugs require the support of data before they can be considered for clinical trials. Several drugs are considered promising therapeutic agents for COVID-19. In addition to the direct-acting antiviral drugs, supportive therapies including traditional Chinese medicine, immunotherapies, immunomodulators, and nutritional therapy could contribute a major role in treating COVID-19 patients. Some of these drugs have already been included in the treatment guidelines, recommendations, and standard operating procedures. In this article, we comprehensively review the approved and potential therapeutic drugs, immune cells-based therapies, immunomodulatory agents/drugs, herbs and plant metabolites, nutritional and dietary for COVID-19.

Citing Articles

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study.

Rao B, Wang D, Yang M, Zhao C, Cheng M, Li S BMC Infect Dis. 2025; 25(1):275.

PMID: 40001043 PMC: 11863899. DOI: 10.1186/s12879-025-10643-w.


Association between COVID-19 severity with liver abnormalities: A retrospective study in a referral hospital in Indonesia.

Maimunah U, Kholili U, Vidyani A, Sugihartono T, Tanaya W, Wessels F Narra J. 2024; 4(2):e816.

PMID: 39280282 PMC: 11391993. DOI: 10.52225/narra.v4i2.816.


Molecular modeling of some commercially available antiviral drugs and their derivatives against SARS-CoV-2 infection.

Arman M, Alam S, Maruf R, Shams Z, Islam M Narra J. 2024; 4(1):e319.

PMID: 38798846 PMC: 11125382. DOI: 10.52225/narra.v4i1.319.


Co-incidence of COVID-19 and hepatocellular carcinoma during pregnancy: Double punches to disease severity and mortality?.

Abubakar A, Yusuf F, Firdausa S, Maghfirah D, Gunawan A, Yeni C Narra J. 2024; 3(3):e264.

PMID: 38455627 PMC: 10919738. DOI: 10.52225/narra.v3i3.264.


The role of N-acetylcysteine in decreasing neutrophil-lymphocyte ratio in COVID-19 patients: A double-blind, randomized controlled trial.

Prabowo N, Megantara M, Apriningsih H Narra J. 2024; 3(2):e121.

PMID: 38454976 PMC: 10919724. DOI: 10.52225/narraj.v3i2.121.


References
1.
Joyner M, Bruno K, Klassen S, Kunze K, Johnson P, Lesser E . Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020; 95(9):1888-1897. PMC: 7368917. DOI: 10.1016/j.mayocp.2020.06.028. View

2.
Galanakis C . The Food Systems in the Era of the Coronavirus (COVID-19) Pandemic Crisis. Foods. 2020; 9(4). PMC: 7230343. DOI: 10.3390/foods9040523. View

3.
Pedersen N, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M . Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 2019; 21(4):271-281. PMC: 6435921. DOI: 10.1177/1098612X19825701. View

4.
Loutfy M, Blatt L, Siminovitch K, Ward S, Wolff B, Lho H . Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003; 290(24):3222-8. DOI: 10.1001/jama.290.24.3222. View

5.
Habibzadeh P, Stoneman E . The Novel Coronavirus: A Bird's Eye View. Int J Occup Environ Med. 2020; 11(2):65-71. PMC: 7205509. DOI: 10.15171/ijoem.2020.1921. View